Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment

Biochem Biophys Res Commun. 2007 Mar 16;354(3):700-6. doi: 10.1016/j.bbrc.2007.01.045. Epub 2007 Jan 17.


The aim of this study was to determine whether intravenously administered multipotent stromal cells from human bone marrow (hMSCs) can improve cardiac function after myocardial infarction (MI) without long-term engraftment and therefore whether transitory paracrine effects or secreted factors are responsible for the benefit conferred. hMSCs were injected systemically into immunodeficient mice with acute MI. Cardiac function and fibrosis after MI in the hMSC-treated group were significantly improved compared with controls. However, despite the cardiac improvement, there was no evident hMSC engraftment in the heart 3 weeks after MI. Microarray assays and ELISAs demonstrated that multiple protective factors were expressed and secreted from the hMSCs in culture. Factors secreted by hMSCs prevented cell death of cultured cardiomyocytes and endothelial cells under conditions that mimicked tissue ischemia. The favorable effects of hMSCs appear to reflect the impact of secreted factors rather than engraftment, differentiation, or cell fusion.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Cells / cytology*
  • Cells, Cultured
  • Enzyme-Linked Immunosorbent Assay
  • Fibrosis / pathology
  • Fibrosis / therapy
  • Humans
  • Mice
  • Multipotent Stem Cells / transplantation*
  • Myocardial Infarction / pathology
  • Myocardial Infarction / therapy*
  • Oligonucleotide Array Sequence Analysis
  • Stromal Cells / transplantation*
  • Time Factors